7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Fine Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Infected Patients: Differential Profiling of Patients With Severe Outcome

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          COVID-19 is caused by the human pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in widespread morbidity and mortality. CD4 + T cells, CD8 + T cells and neutralizing antibodies all contribute to control SARS-CoV-2 infection. However, heterogeneity is a major factor in disease severity and in immune innate and adaptive responses to SARS-CoV-2. We performed a deep analysis by flow cytometry of lymphocyte populations of 125 hospitalized SARS-CoV-2 infected patients on the day of hospital admission. Five clusters of patients were identified using hierarchical classification on the basis of their immunophenotypic profile, with different mortality outcomes. Some characteristics were observed in all the clusters of patients, such as lymphopenia and an elevated level of effector CD8 +CCR7 - T cells. However, low levels of T cell activation are associated to a better disease outcome; on the other hand, profound CD8 + T-cell lymphopenia, a high level of CD4 + and CD8 + T-cell activation and a high level of CD8 + T-cell senescence are associated with a higher mortality outcome. Furthermore, a cluster of patient was characterized by high B-cell responses with an extremely high level of plasmablasts. Our study points out the prognostic value of lymphocyte parameters such as T-cell activation and senescence and strengthen the interest in treating the patients early in course of the disease with targeted immunomodulatory therapies based on the type of adaptive response of each patient.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

          Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease progression suggesting diverse host immune responses. We performed an integrated immune analysis on a cohort of 50 COVID-19 patients with various disease severity. A unique phenotype was observed in severe and critical patients, consisting of a highly impaired interferon (IFN) type I response (characterized by no IFN-β and low IFN-α production and activity), associated with a persistent blood viral load and an exacerbated inflammatory response. Inflammation was partially driven by the transcriptional factor NF-κB and characterized by increased tumor necrosis factor (TNF)-α and interleukin (IL)-6 production and signaling. These data suggest that type-I IFN deficiency in the blood could be a hallmark of severe COVID-19 and provide a rationale for combined therapeutic approaches.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Autoantibodies against type I IFNs in patients with life-threatening COVID-19

            The genetics underlying severe COVID-19 The immune system is complex and involves many genes, including those that encode cytokines known as interferons (IFNs). Individuals that lack specific IFNs can be more susceptible to infectious diseases. Furthermore, the autoantibody system dampens IFN response to prevent damage from pathogen-induced inflammation. Two studies now examine the likelihood that genetics affects the risk of severe coronavirus disease 2019 (COVID-19) through components of this system (see the Perspective by Beck and Aksentijevich). Q. Zhang et al. used a candidate gene approach and identified patients with severe COVID-19 who have mutations in genes involved in the regulation of type I and III IFN immunity. They found enrichment of these genes in patients and conclude that genetics may determine the clinical course of the infection. Bastard et al. identified individuals with high titers of neutralizing autoantibodies against type I IFN-α2 and IFN-ω in about 10% of patients with severe COVID-19 pneumonia. These autoantibodies were not found either in infected people who were asymptomatic or had milder phenotype or in healthy individuals. Together, these studies identify a means by which individuals at highest risk of life-threatening COVID-19 can be identified. Science, this issue p. eabd4570, p. eabd4585; see also p. 404
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

              Summary Proper management of COVID-19 mandates better understanding of disease pathogenesis. The sudden clinical deterioration 7–8 days after initial symptom onset suggests that severe respiratory failure (SRF) in COVID-19 is driven by a unique pattern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression accompanied by profound depletion of CD4 lymphocytes, CD19 lymphocytes, and natural killer (NK) cells. Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) production by circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                15 July 2022
                2022
                15 July 2022
                : 13
                : 889813
                Affiliations
                [1] 1 Laboratoire d’Immunologie, Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes , Grenoble, France
                [2] 2 Cellule d’Ingénierie des Données, Centre Hospitalier Universitaire Grenoble Alpes , Grenoble, France
                [3] 3 Centre d’Investigation Clinique de l’Innovation et de la Technologie (CIC-IT), Centre Hospitalier Universitaire Grenoble Alpes , Grenoble, France
                [4] 4 Service de Maladies Infectieuses, Centre Hospitalier Universitaire Grenoble Alpes , Grenoble, France
                [5] 5 Univ. Grenoble Alpes, CNRS, Grenoble INP, TIMC , Grenoble, France
                [6] 6 Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale , Grenoble, France
                [7] 7 Service de Biochimie Biologie Moléculaire et Toxicologie Environnementale, Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes , Grenoble, France
                [8] 8 Unité recherche, Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes , Grenoble, France
                [9] 9 Laboratoire de Virologie, Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes , Grenoble, France
                [10] 10 Centre d’Investigation Clinique INSERM CIC1406, Centre Hospitalier Universitaire Grenoble Alpes , Grenoble, France
                [11] 11 Univ. Grenoble Alpes, INSERM, UMR 1300, HP2 , Grenoble, France
                Author notes

                Edited by: Giulia Carla Marchetti, University of Milan, Italy

                Reviewed by: Kai Kisand, University of Tartu, Estonia; Camilla Tincati, University of Milan, Italy

                *Correspondence: Giovanna Clavarino, gclavarino@ 123456chu-grenoble.fr

                †These authors have contribute equally to this work and share last authorship

                This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2022.889813
                9335884
                35911748
                75c82059-54f5-4bb8-885f-96e9969d5114
                Copyright © 2022 Clavarino, Leroy, Epaulard, Raskovalova, Vilotitch, Pernollet, Dumestre-Pérard, Defendi, Le Maréchal, Le Gouellec, Audoin, Bosson, Poignard, Roustit, Jacob and Cesbron

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 04 March 2022
                : 27 May 2022
                Page count
                Figures: 3, Tables: 6, Equations: 0, References: 20, Pages: 9, Words: 4126
                Categories
                Immunology
                Original Research

                Immunology
                sars-cov-2,covid-19,lymphocytes,flow cytometry,disease severity
                Immunology
                sars-cov-2, covid-19, lymphocytes, flow cytometry, disease severity

                Comments

                Comment on this article